Methods are provided for determining the responsiveness of, in particular classifying, a patient to a therapy, such as an antibody therapy, e.g.rituximab, and for selecting and/or for treating a subject based on both the H/R 131 FcγRIIA polymorphism and the V/F 158 FcγRIIIA polymorphism. Kits for carrying out the method and methods for optimizing antibody therapies patients based on the responsiveness are also provided. Methods for providing a reference index for correlating treatment response to the nine genotypes are also claimed.
